Browse > Article
http://dx.doi.org/10.4014/jmb.2011.11029

Influenza Chimeric Protein (3M2e-3HA2-NP) Adjuvanted with PGA/Alum Confers Cross-Protection against Heterologous Influenza A Viruses  

Kwak, Chaewon (Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB))
Nguyen, Quyen Thi (Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB))
Kim, Jaemoo (Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB))
Kim, Tae-Hwan (Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB))
Poo, Haryoung (Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB))
Publication Information
Journal of Microbiology and Biotechnology / v.31, no.2, 2021 , pp. 304-316 More about this Journal
Abstract
Vaccination is the most effective way to prevent influenza virus infections. However, conventional vaccines based on hemagglutinin (HA) have to be annually updated because the HA of influenza viruses constantly mutates. In this study, we produced a 3M2e-3HA2-NP chimeric protein as a vaccine antigen candidate using an Escherichia coli expression system. The vaccination of chimeric protein (15 ㎍) conferred complete protection against A/Puerto Rico/8/1934 (H1N1; PR8) in mice. It strongly induced influenza virus-specific antibody responses, cytotoxic T lymphocyte activity, and antibody-dependent cellular cytotoxicity. To spare the dose and enhance the cross-reactivity of the chimeric, we used a complex of poly-γ-glutamic acid and alum (PGA/alum) as an adjuvant. PGA/alum-adjuvanted, low-dose chimeric protein (1 or 5 ㎍) exhibited higher cross-protective effects against influenza A viruses (PR8, CA04, and H3N2) compared with those of chimeric alone or alum-adjuvanted proteins in vaccinated mice. Moreover, the depletion of CD4+ T, CD8+ T, and NK cells reduced the survival rate and efficacy of the PGA/alum-adjuvanted chimeric protein. Collectively, the vaccination of PGA/alum-adjuvanted chimeric protein induced strong protection efficacy against homologous and heterologous influenza viruses in mice, which suggests that it may be a promising universal influenza vaccine candidate.
Keywords
Influenza virus; universal vaccine; adjuvant; cross-reactivity;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Skehel JJ, Wiley DC. 2000. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69: 531-569.   DOI
2 Cross KJ, Langley WA, Russell RJ, Skehel JJ, Steinhauer DA. 2009. Composition and functions of the influenza fusion peptide. Protein Pept. Lett. 16: 766-778.   DOI
3 Wang W, Huang B, Jiang T, Wang X, Qi X, Tan W, et al. 2014. Maximal immune response and cross protection by influenza virus nucleoprotein derived from E. coli using an optimized formulation. Virology 468-470: 265-273.   DOI
4 Mallajosyula VV, Citron M, Ferrara F, Lu X, Callahan C, Heidecker GJ, et al. 2014. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc. Natl. Acad. Sci. USA111: E2514-2523.   DOI
5 Feng J, Zhang M, Mozdzanowska K, Zharikova D, Hoff H, Wunner W, et al. 2006. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol. J. 3: 102.   DOI
6 Liu W, Li H, Chen YH. 2003. N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol. Med. Microbiol. 35: 141-146.   DOI
7 De Filette M, Ramne A, Birkett A, Lycke N, Lowenadler B, Min Jou W, et al. 2006. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24: 544-551.   DOI
8 Yang P, Wang W, Gu H, Li Z, Zhang K, Wang Z, et al. 2014. Protection against influenza H7N9 virus challenge with a recombinant NP-M1-HSP60 protein vaccine construct in BALB/c mice. Antiviral Res. 111: 1-7.   DOI
9 Ameghi A, Pilehvar-Soltanahmadi Y, Baradaran B, Barzegar A, Taghizadeh M, Zarghami N, et al. 2016. Protective immunity against homologous and heterologous influenza virus lethal challenge by immunization with new recombinant chimeric HA2-M2e fusion protein in BALB/C mice. Viral. Immunol. 29: 228-234.   DOI
10 Smalls-Mantey A, Doria-Rose N, Klein R, Patamawenu A, Migueles SA, Ko SY, et al. 2012. Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J. Virol. 86: 8672-8680.   DOI
11 Lai J, Choo JAL, Tan WJ, Too CT, Oo MZ, Suter MA, et al. 2017. TCR-like antibodies mediate complement and antibody-dependent cellular cytotoxicity against Epstein-Barr virus-transformed B lymphoblastoid cells expressing different HLA-A*02 microvariants. Sci. Rep. 7: 9923.   DOI
12 Rimmelzwaan GF, Fouchier RA, Osterhaus AD. 2007. Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr. Opin. Biotechnol. 18: 529-536.   DOI
13 He W, Tan GS, Mullarkey CE, Lee AJ, Lam MM, Krammer F, et al. 2016. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc. Natl. Acad. Sci. USA 113: 11931-11936.   DOI
14 Tan GS, Krammer F, Eggink D, Kongchanagul A, Moran TM, Palese P. 2012. A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J. Virol. 86: 6179-6188.   DOI
15 Wohlbold TJ, Nachbagauer R, Margine I, Tan GS, Hirsh A, Krammer F. 2015. Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses. Vaccine 33: 3314-3321.   DOI
16 Nabel GJ, Fauci AS. 2010. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat. Med. 16: 1389-1391.   DOI
17 Jegaskanda S, Job ER, Kramski M, Laurie K, Isitman G, de Rose R, et al. 2013. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J. Immunol. 190: 1837-1848.   DOI
18 Vemula SV, Sayedahmed EE, Sambhara S, Mittal SK. 2017. Vaccine approaches conferring cross-protection against influenza viruses. Expert. Rev. Vaccines 16: 1141-1154.   DOI
19 Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5: 1157-1163.   DOI
20 Zheng M, Luo J, Chen Z. 2014. Development of universal influenza vaccines based on influenza virus M and NP genes. Infection 42: 251-262.   DOI
21 Lee SY, Kang JO, Chang J. 2019. Nucleoprotein vaccine induces cross-protective cytotoxic T lymphocytes against both lineages of influenza B virus. Clin. Exp. Vaccine Res. 8: 54-63.   DOI
22 Bridges CB, Fukuda K, Uyeki TM, Cox NJ, Singleton JA, Centers for disease C, et al. 2002. Prevention and control of influenza. Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm. Rep. 51: 1-34.
23 Allan W, Tabi Z, Cleary A, Doherty PC. 1990. Cellular events in the lymph node and lung of mice with influenza. Consequences of depleting CD4+ T cells. J. Immunol. 144: 3980-3986.
24 Doherty PC, Topham DJ, Tripp RA, Cardin RD, Brooks JW, Stevenson PG. 1997. Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol. Rev. 159: 105-117.   DOI
25 Eichelberger MC, Wang ML, Allan W, Webster RG, Doherty PC. 1991. Influenza virus RNA in the lung and lymphoid tissue of immunologically intact and CD4-depleted mice. J. Gen. Virol. 72 (Pt 7): 1695-1698.   DOI
26 Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, Fukuda K. 1998. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J. Infect. Dis. 178: 53-60.   DOI
27 Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, et al. 2009. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr. Infect. Dis. J. 28: 563-571.   DOI
28 Macleod MK, David A, Jin N, Noges L, Wang J, Kappler JW, et al. 2013. Influenza nucleoprotein delivered with aluminium salts protects mice from an influenza A virus that expresses an altered nucleoprotein sequence. PLoS One 8: e61775.   DOI
29 McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, et al. 2013. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect. Dis. 13: 485-496.   DOI
30 Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, Xu L, et al. 2005. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23: 5404-5410.   DOI
31 Nguyen QT, Kwak C, Lee WS, Kim J, Jeong J, Sung MH, et al. 2019. Poly-gamma-Glutamic acid complexed with alum induces cross-protective immunity of pandemic H1N1 vaccine. Front. Immunol. 10: 1604.   DOI
32 Tsybalova LM, Stepanova LA, Shuklina MA, Mardanova ES, Kotlyarov RY, Potapchuk MV, et al. 2018. Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine. PLoS One 13: e0201429.   DOI
33 Stepanova LA, Mardanova ES, Shuklina MA, Blokhina EA, Kotlyarov RY, Potapchuk MV, et al. 2018. Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes. J. Biomed. Sci. 25: 33.   DOI
34 Kim YJ, Lee YT, Kim MC, Lee YN, Kim KH, Ko EJ, et al. 2017. Cross-protective efficacy of influenza virus M2e containing virus-like particles is superior to hemagglutinin vaccines and variable depending on the genetic backgrounds of mice. Front. Immunol. 8: 1730.   DOI
35 Yang J, Shim SM, Nguyen TQ, Kim EH, Kim K, Lim YT, et al. 2017. Poly-gamma-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine. Sci. Rep. 7: 44839.   DOI
36 Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Epidemiol. 27: 493-497.   DOI
37 Nichol KL, Treanor JJ. 2006. Vaccines for seasonal and pandemic influenza. J. Infect. Dis. 194 Suppl 2: S111-118.   DOI
38 Frace AM, Klimov AI, Rowe T, Black RA, Katz JM. 1999. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 17: 2237-2244.   DOI
39 Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ. 1995. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 13: 1399-1402.   DOI
40 Webster RG, Laver WG. 1972. The origin of pandemic influenza. Bull World Health Organ. 47: 449-452.
41 Gerhard W, Mozdzanowska K, Zharikova D. 2006. Prospects for universal influenza virus vaccine. Emerg. Infect. Dis. 12: 569-574.   DOI
42 Atmar RL, Keitel WA, Cate TR, Munoz FM, Ruben F, Couch RB. 2007. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine 25: 5367-5373.   DOI
43 Martin Mdel P, Seth S, Koutsonanos DG, Jacob J, Compans RW, Skountzou I. 2010. Adjuvanted influenza vaccine administered intradermally elicits robust long-term immune responses that confer protection from lethal challenge. PLoS One 5: e10897.   DOI
44 Ada GL, Jones PD. 1986. The immune response to influenza infection. Curr. Top Microbiol. Immunol. 128: 1-54.   DOI
45 Kim MC, Song JM, O E, Kwon YM, Lee YJ, Compans RW, et al. 2013. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol. Ther. 21: 485-492.   DOI
46 Yang M, Berhane Y, Salo T, Li M, Hole K, Clavijo A. 2008. Development and application of monoclonal antibodies against avian influenza virus nucleoprotein. J. Virol. Methods 147: 265-274.   DOI
47 Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD, et al. 2004. Mapping the antigenic and genetic evolution of influenza virus. Science 305: 371-376.   DOI
48 van de Sandt CE, Kreijtz JH, Rimmelzwaan GF. 2012. Evasion of influenza A viruses from innate and adaptive immune responses. Viruses 4: 1438-1476.   DOI
49 Saunders-Hastings PR, Krewski D. 2016. Reviewing the history of pandemic influenza: Understanding patterns of emergence and transmission. Pathogens. 5: 66.   DOI
50 Lee YN, Lee YT, Kim MC, Gewirtz AT, Kang SM. 2016. A novel vaccination strategy mediating the induction of lung-resident memory CD8 T cells confers heterosubtypic immunity against future pandemic influenza virus. J. Immunol. 196: 2637-2645.   DOI
51 Asthagiri Arunkumar G, Ioannou A, Wohlbold TJ, Meade P, Aslam S, Amanat F, et al. 2019. Broadly cross-reactive, nonneutralizing antibodies against influenza B Virus hemagglutinin demonstrate effector function-dependent protection against lethal viral challenge in mice. J Virol. 93: e01696-18.
52 Park SJ, Si YJ, Kim J, Song MS, Kim SM, Kim EH, et al. 2016. Cross-protective efficacies of highly-pathogenic avian influenza H5N1 vaccines against a recent H5N8 virus. Virology 498: 36-43.   DOI
53 Jegaskanda S, Weinfurter JT, Friedrich TC, Kent SJ. 2013. Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J. Virol. 87: 5512-5522.   DOI
54 Wang TT, Tan GS, Hai R, Pica N, Ngai L, Ekiert DC, et al. 2010. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl. Acad. Sci. USA 107: 18979-18984.   DOI
55 DiLillo DJ, Tan GS, Palese P, Ravetch JV. 2014. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat. Med. 20: 143-151.   DOI
56 Black RA, Rota PA, Gorodkova N, Klenk HD, Kendal AP. 1993. Antibody response to the M2 protein of influenza A virus expressed in insect cells. J. Gen. Virol. 74 (Pt 1): 143-146.   DOI
57 Canaday DH, Gehring A, Leonard EG, Eilertson B, Schreiber JR, Harding CV, et al. 2003. T-cell hybridomas from HLA-transgenic mice as tools for analysis of human antigen processing. J. Immunol. Methods 281: 129-142.   DOI
58 Tutykhina I, Esmagambetov I, Bagaev A, Pichugin A, Lysenko A, Shcherbinin D, et al. 2018. Vaccination potential of B and T epitope-enriched NP and M2 against Influenza A viruses from different clades and hosts. PLoS One 13: e0191574.   DOI
59 Jameson J, Cruz J, Terajima M, Ennis FA. 1999. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J. Immunol. 162: 7578-7583.
60 Gianfrani C, Oseroff C, Sidney J, Chesnut RW, Sette A. 2000. Human memory CTL response specific for influenza A virus is broad and multispecific. Hum. Immunol. 61: 438-452.   DOI
61 Misplon JA, Lo CY, Gabbard JD, Tompkins SM, Epstein SL. 2010. Genetic control of immune responses to influenza A matrix 2 protein (M2). Vaccine 28: 5817-5827.   DOI
62 Mezhenskaya D, Isakova-Sivak I, Rudenko L. 2019. M2e-based universal influenza vaccines: a historical overview and new approaches to development. J. Biomed. Sci. 26: 76.   DOI
63 Grebe KM, Yewdell JW, Bennink JR. 2008. Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect. 10: 1024-1029.   DOI
64 Palese P. 2004. Influenza: old and new threats. Nat. Med. 10: S82-87.   DOI
65 Te Velthuis AJ, Fodor E. 2016. Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis. Nat. Rev. Microbiol. 14: 479-493.   DOI
66 Lee YN, Kim MC, Lee YT, Hwang HS, Lee J, Kim C, et al. 2015. Cross protection against influenza A virus by yeast-expressed heterologous tandem repeat M2 extracellular proteins. PLoS One 10: e0137822.   DOI
67 Chen J, Deng YM. 2009. Influenza virus antigenic variation, host antibody production and new approach to control epidemics. Virol. J. 6: 30.   DOI
68 World Health Organization. 2018. Influenza (Seasonal). Available from https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal). Accessed Nov. 10, 2020.
69 Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, et al. 2010. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 1: e00018-10.
70 Wang W, Huang B, Jiang T, Wang X, Qi X, Gao Y, et al. 2012. Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coli. PLoS One 7: e52488.   DOI
71 Goff PH, Eggink D, Seibert CW, Hai R, Martinez-Gil L, Krammer F, et al. 2013. Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. PLoS One 8: e79194.   DOI
72 Shim BS, Choi YK, Yun CH, Lee EG, Jeon YS, Park SM, et al. 2011. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. PLoS One 6: e27953.   DOI